AdvanCell Secures $112M Series C to Expand Radionuclide Cancer Therapies

  • AdvanCell has raised $112 million in an oversubscribed Series C funding round, co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis.
  • The investment will expand manufacturing capacity and accelerate clinical development of its radionuclide therapies, including the ADVC001 clinical trial for metastatic prostate cancer.

AdvanCell, a radiopharmaceuticals biotech, has secured $112 million in an oversubscribed Series C financing round. The funding was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis, with additional participation from Morningside, Tenmile, Brandon Capital, and others.

The investment will support AdvanCell’s manufacturing expansion and clinical development of its targeted radionuclide therapies. The company is currently conducting a Phase I/II dose escalation trial for ADVC001, a Pb-212-based Targeted Alpha Therapy for metastatic prostate cancer. This trial aims to demonstrate the safety and efficacy of the therapy.

As part of the funding round, Jamil M. Beg (SV Health Investors), Christopher Gagliardi (Sanofi Ventures), and Bali Muralidhar (Abingworth) have joined the AdvanCell Board of Directors. They will work alongside existing directors Bill Ferris AC, Anthony Aiudi, Kevin Cameron, and Andrew Adamovich to guide the company’s growth.

“This successful Series C round demonstrates strong confidence in our vision and capabilities,” said Andrew Adamovich, CEO of AdvanCell. “With this funding, AdvanCell is well-positioned to scale our manufacturing operations and progress our cutting-edge therapies towards commercialization.”

Founded in 2019, AdvanCell has expanded into a global organisation with a 40,000-square-foot manufacturing facility, world-class preclinical infrastructure, and a growing pipeline of radionuclide-based cancer treatments. The company aims to transform cancer care through Targeted Alpha Therapy, leveraging the radiobiological properties of Pb-212 to develop life-changing treatments for patients.

Sign up to the free weekly newsletter for all the latest biotech news, resources and podcasts.  Register here

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

UPCOMING EVENT

New from PharmaSource, CDMO Live (Rotterdam, May 7-8, 2025) brings together biopharma’s manufacturing leaders to optimise their outsourcing strategy.

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.